This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Selexipag is a  pulmonary vasodilator medication developed by the U.S. Food And Drug Administration and initially approved in the year 2015, for treating pulmonary arterial hypertension (PAH)

Mechanism of Action of undefined

Selexipag works by activating the prostacyclin receptors in the blood vessels of the lungs. This activation leads to the relaxation and widening of the blood vessels, reducing the elevated blood pressure in the pulmonary arteries. By dilating the blood vessels, this drug improves blood flow and reduces the workload on the heart.

Uses of undefined

Selexipag is used to treat pulmonary arterial hypertension (PAH) to improve exercise capacity and delay disease progression. Pulmonary arterial hypertension is a serious and rare medical condition caused by high blood pressure in the arteries that supply the lungs. It primarily affects the small blood vessels (arteries) in the lungs, leading to their narrowing and increased resistance to blood flow.

undefined Drug administaration and Dosage available

Selexipag is a prescription medicine available as a tablet in various doses, Selexipag 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

Warnings, Precautions and Side Effects of undefined


Selexipag is contraindicated in individuals with known hypersensitivity or allergy to it or its component. It is also contraindicated if you have certain heart conditions such as severe coronary heart disease, unstable angina, recent heart attack, decompensated cardiac failure, severe irregular heartbeat, or certain heart valve defects. Also, if you have had a stroke within the last three months or any other event that reduces blood supply to the brain or are taking gemfibrozil (a medication used to lower lipid levels), this drug should not be taken.


If you have issues with your thyroid gland, it is necessary to inform your physician. Thyroid problems can impact the treatment plan, and your doctor will consider the potential effects of this drug on your condition. This drug is contraindicated during pregnancy because it can harm a developing fetus, and breastfeeding is not recommended in patients taking Selexipag because it is unknown whether the medicine passes into the breast milk and harms your baby. This drug is metabolized and excreted by the kidneys, so if you have severe kidney problems or are undergoing dialysis, your doctor needs to determine the appropriate dosage or prescribe an alternative medicine if necessary.

Side Effects

The side effects known to occur commonly during the treatment with Selexipag are weight loss, stomach pain, rashes, hyperthyroidism, and reduced appetite. Some serious side effects also include headache, diarrhea, reddening of face, vomiting, nausea, pain in the jaws, muscles, legs, or joints, and stuffy nose.

Word Of Advice

Since this medication aims to reduce joint pain, swelling, and stiffness, it may take several weeks or months to experience the full benefits of Selexipag, so be patient and continue taking it as directed.

Frequently Asked Question


  1. Janssen-Cilag Limited, Electronic medicines compendium (EMC), [Revised on June 2022] [ Accessed on 18th July 2023],
  2. Actelion Pharmaceutical US, US Food and Drug Administration, [Revised on Dec 2017] [ Accessed on 18th July 2023],
  3. Olivier Sitbon et al.; Selexipag for the Treatment of Pulmonary Arterial Hypertension; The New England Journal of Medicine; Published on Dec 2015; Accessed on 18/07/2023;


The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.